Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes

dc.contributor.author	Turan, V.
dc.contributor.author	Bedoschi, G.
dc.contributor.author	Emirdar, V.
dc.contributor.author	Moy, F.
dc.contributor.author	Oktay, K.
dc.date.accessioned	2021-12-21T08:41:10Z
dc.date.available	2021-12-21T08:41:10Z
dc.date.issued	2018
dc.identifier.issn	19337191
dc.identifier.uri	https://doi.org/10.1177/1933719117728800
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1345
dc.description.abstract	Background: Aromatase inhibitors (AI) have been introduced to reduce estrogen exposure in women with estrogen-sensitive cancer undergoing ovarian stimulation for oocyte/embryo cryopreservation. There have been questions regarding whether the addition of A
dc.language.iso	English
dc.publisher	SAGE Publications Inc.
dc.title	Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes
dc.type	Article
dc.relation.journal	Reproductive Sciences
dc.identifier.issue	1
dc.identifier.startpage	26
dc.identifier.endpage	32
dc.identifier.volume	25
dc.identifier.doi	10.1177/1933719117728800
dc.relation.issue	1
dc.relation.volume	25

Files in this item

Files	Size	Format	View
There are no files associated with this item.